Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Go back to Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
(NASDAQ: ATRA) Delayed: 9.35 +0.19 (2.07%)
Previous Close $9.16    52 Week High $40.80 
Open $9.25    52 Week Low $12.45 
Day High $9.43    P/E N/A 
Day Low $9.17    EPS $0.00 
Volume 26,545